Nyxoah's Q2 2025 earnings call highlighted the significant milestone of FDA approval for the Genio system and strong revenue growth, indicating a positive launch trajectory in the U.S. However, increased operating losses and a reduced cash position, along with a patent lawsuit, present challenges that temper the overall outlook.

Company Guidance

During Nyxoah's Second Quarter 2025 Earnings Conference Call, CEO Olivier Taelman announced the FDA PMA approval for the Genio system in the U.S., emphasizing its significance as the first and only bilateral HGNS approved for obstructive sleep apnea (OSA), without contraindications for complete concentric collapse (CCC). The DREAM study, demonstrating 85.9% compliance and 90% patient satisfaction, supports the system's efficacy. CFO John Landry reported a 73.8% revenue increase to EUR 1.3 million and a gross margin of 63.4%. Nyxoah's cash position stood at EUR 43 million, with EUR 27.5 million available under a term debt facility. The U.S. launch involves a team of over 50 professionals targeting key implanting centers and developing referral networks, with early VAC and pre-authorization approvals already achieved.

FDA PMA Approval for Genio System

Nyxoah received FDA PMA approval for their Genio system in the United States, marking the first and only bilateral HGNS approved in the U.S. for the treatment of obstructive sleep apnea (OSA).

Significant Revenue Growth

Nyxoah recorded revenue of EUR 1.3 million in Q2 2025, representing an increase of 73.8% compared to EUR 800,000 in Q2 2024.

Successful U.S. Launch Strategy

Nyxoah initiated a focused U.S. launch with over 50 commercial professionals and achieved several VAC and pre-authorization approvals in the first week.

High Patient Satisfaction and Compliance

The DREAM study published in the Journal of Clinical Sleep Medicine showed patient satisfaction scored at 90% and compliance at 85.9%.

Nyxoah (NYXH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NYXH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.68 / -	-0.578	―	―	―
Aug 18, 2025	2025 (Q2)	-0.66 / -0.64	-0.499	-28.74% (-0.14)	―
May 14, 2025	2025 (Q1)	-0.55 / -0.70	-0.484	-44.10% (-0.21)	―
Mar 13, 2025	2024 (Q4)	-0.55 / -0.54	-0.442	-22.16% (-0.10)	―
Nov 06, 2024	2024 (Q3)	-0.53 / -0.58	-0.31	-86.47% (-0.27)	―
Aug 06, 2024	2024 (Q2)	-0.50 / -0.50	-0.521	4.25% (+0.02)	―
May 14, 2024	2024 (Q1)	-0.49 / -0.48	-0.536	9.78% (+0.05)	―
Mar 05, 2024	2023 (Q4)	-0.42 / -0.44	-0.599	26.26% (+0.16)	―
Nov 08, 2023	2023 (Q3)	-0.51 / -0.31	-0.282	-9.92% (-0.03)	―
Aug 08, 2023	2023 (Q2)	-0.48 / -0.52	-0.225	-131.61% (-0.30)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NYXH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 18, 2025	$6.57	$6.27	-4.57%
May 14, 2025	$5.78	$6.06	+4.84%
Mar 13, 2025	$9.73	$10.05	+3.29%
Nov 06, 2024	$10.00	$9.64	-3.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nyxoah (NYXH) report earnings?

Nyxoah (NYXH) is schdueled to report earning on Nov 13, 2025, After Close (Confirmed).

What is Nyxoah (NYXH) earnings time?

Nyxoah (NYXH) earnings time is at Nov 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NYXH EPS forecast?

NYXH EPS forecast for the fiscal quarter 2025 (Q3) is -0.68.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing